Core Viewpoint - The CXO sector in China is showing signs of recovery, with several companies, including WuXi AppTec, announcing a return to growth in their mid-term performance forecasts [1] Company Performance - WuXi AppTec has raised its full-year sales forecast, expecting a return to double-digit growth in revenue for its continuing operations by 2025, with the growth rate adjusted from 10%-15% to 13%-17% [1] - In the first half of the year, WuXi AppTec reported revenue of 20.799 billion yuan, a year-on-year increase of 20.64%, and a net profit attributable to shareholders of 8.561 billion yuan, up 101.92% [1] - In the second quarter, WuXi AppTec achieved a record revenue of 11.145 billion yuan and a net profit of 4.889 billion yuan [1] Industry Insights - According to CICC, the expected increase in business development funds and secondary market activity will boost domestic new drug research and development demand, as well as enhance the financing activity of primary innovative drug projects, benefiting domestic companies [1] - The cost and efficiency advantages of Chinese companies are attracting overseas clients, leading to a positive trend in external demand orders [1]

Core Viewpoint - On July 25, the Hang Seng Index fell by 1.09%, closing at 25,388.35 points, while southbound funds through the Stock Connect recorded a net purchase of HKD 20.184 billion [1][2]. Group 1: Market Activity - The total trading volume for the Stock Connect on July 25 was HKD 148.55 billion, with a net purchase of HKD 20.184 billion [1]. - The Shanghai Stock Connect accounted for HKD 92.243 billion in trading volume, with a net purchase of HKD 11.474 billion, while the Shenzhen Stock Connect had a trading volume of HKD 56.308 billion and a net purchase of HKD 8.710 billion [1]. Group 2: Active Stocks - The most actively traded stock in the Shanghai Stock Connect was the Tracker Fund of Hong Kong (盈富基金), with a trading volume of HKD 49.37 billion and a net purchase of HKD 49.02 billion, despite a closing price drop of 1.07% [1][2]. - Other notable stocks included SMIC (中芯国际) and Alibaba (阿里巴巴-W), with trading volumes of HKD 40.80 billion and HKD 26.25 billion, respectively [1]. - In the Shenzhen Stock Connect, the Tracker Fund of Hong Kong also led with a trading volume of HKD 24.22 billion and a net purchase of HKD 23.78 billion, while the stock closed down by 1.07% [2].

Core Insights - The Hang Seng Index fell by 1.09% on July 25, with southbound trading totaling HKD 148.55 billion, including HKD 84.37 billion in buying and HKD 64.18 billion in selling, resulting in a net buying amount of HKD 20.18 billion [1] Trading Activity - The most active stock in southbound trading was the Tracker Fund of Hong Kong (盈富基金), with a total trading amount of HKD 73.58 billion and a net buying amount of HKD 72.80 billion, despite a closing price drop of 1.07% [1][2] - Other notable stocks included SMIC (中芯国际) with a trading amount of HKD 64.69 billion and a net buying of HKD 7.82 billion, and Alibaba (阿里巴巴-W) with a trading amount of HKD 45.97 billion and a net buying of HKD 8.24 million [2] Net Buying and Selling - A total of 9 stocks experienced net buying, with the Tracker Fund of Hong Kong leading at HKD 72.80 billion, followed by the Hang Seng China Enterprises Index (恒生中国企业) with HKD 14.35 billion and China Life (中国人寿) with HKD 9.55 billion [1] - The stock with the highest net selling was Kuaishou (快手-W), with a net selling amount of HKD 6.67 billion and a closing price drop of 4.86% [1][2]

Core Viewpoint - On July 25, WuXi Biologics made its first appearance on the Hong Kong Stock Connect active trading list in a month, indicating increased investor interest in the stock [2]. Group 1: Trading Activity - On July 25, the total trading volume of active stocks on the Hong Kong Stock Connect reached HKD 420.49 billion, accounting for 28.31% of the day's total trading amount [2]. - The net buying amount for the day was HKD 110.89 billion [2]. - The top three stocks by trading volume were: - Tracker Fund of Hong Kong (HKD 73.58 billion) - SMIC (HKD 64.69 billion) - Alibaba-W (HKD 45.97 billion) [2]. Group 2: Stock Performance - WuXi Biologics had a trading volume of HKD 10.13 billion on the same day, with a net sell amount of HKD 1.98 billion, and its stock price increased by 5.53% [2]. - The stocks with the highest number of appearances on the active trading list over the past month were Alibaba-W and Guotai Junan International, each appearing 21 times, indicating strong interest from Hong Kong Stock Connect funds [2].

Core Insights - On July 25, 2025, the top three companies by trading volume in the southbound Shanghai-Hong Kong Stock Connect were Yingfu Fund (02800), SMIC (00981), and Alibaba-W (09988) with trading volumes of 4.937 billion, 4.080 billion, and 2.625 billion respectively [1] - The same companies also led the trading volume in the southbound Shenzhen-Hong Kong Stock Connect, with volumes of 2.422 billion, 2.389 billion, and 1.971 billion respectively [1] Southbound Shanghai-Hong Kong Stock Connect - The top active trading companies included: - Yingfu Fund (02800) with a trading amount of 4.937 billion and a net buying amount of 4.902 billion [2] - SMIC (00981) with a trading amount of 4.080 billion and a net buying amount of 0.444 billion [2] - Alibaba-W (09988) with a trading amount of 2.625 billion and a net buying amount of 0.139 billion [2] - Other notable companies included Tencent Holdings (00700) with 2.247 billion and a net buying amount of 0.248 billion, and Xiaomi Group-W (01810) with 2.200 billion and a net buying amount of 0.547 billion [2] Southbound Shenzhen-Hong Kong Stock Connect - The top active trading companies included: - Yingfu Fund (02800) with a trading amount of 2.422 billion and a net buying amount of 2.378 billion [2] - SMIC (00981) with a trading amount of 2.389 billion and a net buying amount of 0.338 billion [2] - Alibaba-W (09988) with a trading amount of 1.971 billion and a net selling amount of 0.568 billion [2] - Other notable companies included Tencent Holdings (00700) with 1.830 billion and a net selling amount of 0.128 billion, and Meituan-W (03690) with 1.631 billion and a net buying amount of 0.206 billion [2]

Group 1 - The Hong Kong stock market saw a net inflow of 201.84 billion HKD from Northbound trading on July 25, with 114.74 billion HKD from Shanghai and 87.1 billion HKD from Shenzhen [1] - The most bought stocks included the Tracker Fund of Hong Kong (02800), Hang Seng China Enterprises (02828), and China Life (02628), while Guotai Junan International (01788) was the most sold stock [1][9] Group 2 - The Tracker Fund of Hong Kong (02800) received a net inflow of 49.19 billion HKD, while China Life (02628) saw a net inflow of 9.54 billion HKD, attributed to its perceived value as a substitute for Chinese interest rates [6][7] - Semiconductor company SMIC (00981) had a net inflow of 7.81 billion HKD, driven by optimistic growth projections in the global semiconductor market [7] - Meituan (03690), Tencent (00700), and Alibaba (09988) also experienced net inflows of 3.3 billion HKD, 1.19 billion HKD, and 823.6 million HKD respectively, as market expectations for their upcoming earnings reports remain high [7] Group 3 - Three-Six Bio (01530) received a net inflow of 3.15 billion HKD following the establishment of a licensing agreement with Pfizer for a dual-specific antibody [8] - Xiaomi Group (01810) attracted a net inflow of 7.7 billion HKD, while Guotai Junan International (01788) faced a net outflow of 1.16 billion HKD [9]

Market Overview - The Hong Kong stock market experienced a decline, with the Hang Seng Index dropping over 1%, ending a five-day winning streak, closing at 25,388.35 points, down 1.09% or 278.83 points, with a total turnover of 281.77 billion HKD [1] - Despite the decline, the Hang Seng Index saw a weekly increase of 2.27%, while the Hang Seng China Enterprises Index and the Hang Seng Tech Index rose by 1.83% and 2.51% respectively [1] Blue Chip Performance - WuXi Biologics (02269) led the blue-chip stocks, rising 5.53% to 31.5 HKD, contributing 9.65 points to the Hang Seng Index, following a profit warning indicating a projected 16% revenue growth in the first half of 2025 [2] - Other notable blue-chip performances included SMIC (00981) up 4.98%, Nongfu Spring (09633) up 3.56%, while New Oriental (09901) and Shenzhou International (02313) saw declines of 3.36% and 2.94% respectively [2] Sector Highlights - Large tech stocks generally declined, with Alibaba down nearly 2% and Tencent over 1% [3] - Semiconductor stocks saw a rally, with Hua Hong Semiconductor rising 9% and SMIC up nearly 5% [3] - The pharmaceutical sector experienced gains, driven by a shift towards value assessment in drug procurement, with notable increases in stocks like Kanglong Chemical (03759) up 7.71% and Zhaoyan New Drug (06127) up 7.02% [4] - Airline stocks were active, with China Eastern Airlines (00670) up 3.69% and Air China (00753) up 3.68%, supported by strong summer travel demand [6][7] Regulatory Developments - The National Healthcare Security Administration announced changes to the 11th batch of centralized procurement, moving away from a simple lowest price reference, which is expected to curb vicious price competition and promote a shift towards value-based competition in the pharmaceutical industry [5] - The introduction of new policies aimed at supporting innovative drugs and medical devices was discussed in a recent meeting, indicating a focus on enhancing the clinical application of high-level technological innovations [5] Notable Stock Movements - Valiant Biopharma (09887) saw a significant increase of 91.71% on its debut, closing at 67.1 HKD, following a successful IPO [9] - Jihong Holdings (02603) rose 15.31% after announcing a projected net profit increase of 97.25% to 108.21% for the first half of 2025 [10] - COSCO Shipping Ports (01199) reached a new high, up 9.31%, amid reports of potential acquisitions of port assets [11] - Kintor Pharmaceutical (00148) announced a profit warning, leading to an 8.29% increase in stock price, with expected profits rising over 70% [12] - Lingbao Gold (03330) also saw gains, up 5.89%, with projected revenue growth of 75% to 85% for the first half of 2025 [13]

Summary of WuXi Biologics Conference Call Company Overview - **Company**: WuXi Biologics (2269.HK) - **Market Cap**: HK$122.4 billion / $15.6 billion - **Enterprise Value**: HK$119.8 billion / $15.3 billion - **Current Price**: HK$28.75 - **12-Month Price Target**: HK$25.60 - **Downside Potential**: 11.0% [1][5][18] Key Financial Highlights - **1H25 Preliminary Revenue Growth**: +16% year-over-year (y/y) [1] - **Net Profit Growth**: +56% y/y, slightly above market expectations [1] - **Gross Margin Expansion**: Increased by 3.6 percentage points y/y, attributed to milestone bookings in the "R" segment [1] - **Utilization Improvement**: Enhanced utilization of newly released capacity, particularly from WuXi XDC, and reduced losses from the Ireland site [1] - **Administrative Expenses**: Lowered due to a decline in share-based compensation, contributing to an 11% y/y increase in adjusted non-IFRS net profit [1] Future Outlook and Investor Concerns - **New Order Growth**: Expected growth of +13-15% y/y for continuing operations in FY24, with investor concerns regarding a slight decline in new orders excluding WuXi XDC [2] - **Visibility on Late-Stage Projects**: As of year-end 2024, the company reported 66 Phase III and 21 commercial projects, enhancing revenue predictability [3] - **Milestone Payments**: Near-term milestone payments are projected to reach US$140 million, with half expected to be booked in 2H24 and the remainder in 1H25 [3] Capital Expenditure and Expansion Plans - **Capex Guidance for FY25**: Management has guided for Rmb6.0 billion in capital expenditures, focusing on expansions in the US and Singapore [17] - **Specific Allocations**: Rmb1.4 billion earmarked for WuXi XDC's capacity expansion, with total budget estimates of US$500 million for the US site and US$2 billion for the Singapore site [17] Risks and Methodology - **Price Target Risks**: - Upside risk if legislation affects only federally funded projects or excludes WuXi names - Downside risks include potential legislative scenarios that could exclude US or ex-China revenue, cooling biotech funding, and increased competition [18] Financial Projections - **Revenue Forecasts**: - FY24: Rmb18,675.4 million - FY25: Rmb21,276.5 million - FY26: Rmb24,012.1 million - FY27: Rmb27,094.6 million [5][12] - **EBITDA and EPS Growth**: Projected EBITDA growth of 13.8% in FY24 and EPS growth of 15.3% in FY25 [12] Conclusion WuXi Biologics is positioned for growth with strong revenue and profit increases, but faces challenges related to new order momentum and external market conditions. The company's strategic focus on capacity expansion and milestone payments will be critical in maintaining its growth trajectory. Investors should remain cautious of legislative risks and competitive pressures in the biotech sector.

Group 1: Market Overview - The Hang Seng Index fell by 1.11%, down 284 points, closing at 25,383 points, while the Hang Seng Tech Index dropped by 1.69% [1] - The early trading volume in Hong Kong stocks reached 151 billion HKD [1] Group 2: Medical Sector - Medical device stocks rose in early trading, with the national drug procurement policy indicating a move away from internal competition, leading institutions to view this as a turning point for the industry [1] - Aikang Medical (01789) increased by 7.93%, and Weigao Group (01066) rose by 4.37% [1] - Yongsheng Medical (01612) saw a surge of over 27% following a profit warning, with sales orders increasing and expected mid-term net profit growth exceeding 50% year-on-year [2] - CRO concept stocks continued to rise, with Citigroup noting that the CXO sector is gaining market attention ahead of earnings season [2] - Kanglong Chemical (300759) (03759) rose by 8.4%, while Zhaoyan New Drug (603127) (06127) increased by 5.7%, and WuXi Biologics (02269) rose by 4.5% [2] Group 3: Consumer Sector - Nongfu Spring (09633) increased by over 3.56%, reaching a three-and-a-half-year high, with institutions expecting the company's first-half revenue growth to exceed market expectations [3] Group 4: Other Notable Stocks - Jihong Co., Ltd. (002803) (02603) rose by 16%, with two main business segments performing well, and expected first-half net profit growth of up to 65% [4] - China Merchants Port (01199) increased by over 4%, following reports that China Merchants Group plans to acquire assets from Cheung Kong Ports [5] - Guichuang Tongqiao (02190) rose by 2.6%, with expected mid-term net profit growth of 66.9%, as the company embraces procurement and actively expands overseas [6] Group 5: Lithium and Duty-Free Sector - News of supply disruptions in the lithium market led to Tianqi Lithium (002466) (09696) rising by 3.6% [7] - China Duty Free Group (601888) (01880) fell by over 6%, with pending details on Hainan's duty-free policies, and institutions noting that the closure operations have a dual impact on offshore duty-free business [7] Group 6: Technology Sector - Qianxun Technology (01640) fell by over 3%, having retreated 23% from its previous high, with recent comments from Yu Weiwen emphasizing the need to avoid excessive speculation on stablecoins [8]

Group 1: Market Performance - The pharmaceutical sector showed strength in early trading on July 25, with the Biopharmaceutical ETF (159859) having a turnover rate exceeding 3.5% and a transaction volume of over 1.11 billion yuan, leading among its peers [1] - The Medical Devices ETF (159873) increased by 0.82% with a turnover rate over 8.1%, featuring stocks like Kangtai Medical hitting the daily limit [1] - The Innovation Drug ETF Tianhong (517380) rose by 0.79% with a turnover rate exceeding 1.8%, and its constituent stocks included Kanglong Chemical and WuXi Biologics, which saw significant gains [1] Group 2: ETF Characteristics - The Biopharmaceutical ETF (159859) closely tracks the National Index of Biopharmaceuticals (399441.SZ), covering various sectors such as innovative drugs, CXO, vaccines, and blood products, making it the largest and most liquid product in its category [1] - The Innovation Drug ETF Tianhong (517380) is the largest in the market, spanning the Shanghai, Shenzhen, and Hong Kong markets, and is the only ETF tracking the Hang Seng Shanghai-Shenzhen-Hong Kong Innovation Drug Select 50 Index, which has a cumulative weight of nearly 60% in its top ten constituents [2] Group 3: Industry Insights - Jianghai Securities emphasizes the importance of focusing on innovative drug companies with rich R&D pipelines and suggests investing in the entire innovative drug industry chain due to its potential for strong synergistic development [3] - Everbright Securities recommends focusing on two types of targets: those that have consistently been selected in centralized procurement and possess dual advantages in quality and cost, and innovative drug companies with rich R&D pipelines whose core products are entering medical insurance or are expected to be included in the innovative drug catalog [3]